Literature DB >> 11248401

Reduction of large neutral amino acid levels in plasma and brain of hyperleucinemic rats.

P Araújo1, G F Wassermann, K Tallini, V Furlanetto, C R Vargas, C M Wannmacher, C S Dutra-Filho, A T Wyse, M Wajner.   

Abstract

Neurological dysfunction is common in patients with maple syrup urine disease (MSUD). However, the mechanisms underlying the neuropathology of this disorder are poorly known. In the present study we investigated the effect of acute hyperleucinemia on plasma and brain concentrations of amino acids. Fifteen-day-old rats were injected subcutaneously with 6 micromol L-leucine per gram body weight. Controls received saline in the same volumes. The animals were sacrificed 30--120 min after injection, blood was collected and their brain rapidly removed and homogenized. The amino acid concentrations were determined by HPLC using orthophtaldialdehyde for derivatization and fluorescence for detection. The results showed significant reductions of the large neutral amino acids (LNAA) L-phenylalanine, L-tyrosine, L-isoleucine, L-valine and L-methionine, as well as L-alanine, L-serine and L-histidine in plasma and of L-phenylalanine, L-isoleucine, L-valine and L-methionine in brain, as compared to controls. In vitro experiments using brain slices to study the influence of leucine on amino acid transport and protein synthesis were also carried out. L-Leucine strongly inhibited [14C]-L-phenylalanine transport into brain, as well as the incorporation of the [14C]-amino acid mixture, [14C]-L-phenylalanine and [14C]-L-lysine into the brain proteins. Although additional studies are necessary to evaluate the importance of these effects for MSUD, considering previous findings of reduced levels of LNAA in plasma and CSF of MSUD patients during crises, it may be speculated that a decrease of essential amino acids in brain may lead to reduction of protein and neurotransmiter synthesis in this disorder.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11248401     DOI: 10.1016/s0197-0186(00)00100-5

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  32 in total

1.  Creatine and antioxidant treatment prevent the inhibition of creatine kinase activity and the morphological alterations of C6 glioma cells induced by the branched-chain alpha-keto acids accumulating in maple syrup urine disease.

Authors:  Cláudia Funchal; Patrícia Fernanda Schuck; André Quincozes Dos Santos; Maria Caroline Jacques-Silva; Carmem Gottfried; Regina Pessoa-Pureur; Moacir Wajner
Journal:  Cell Mol Neurobiol       Date:  2006-02       Impact factor: 5.046

2.  Effect of pluronic p85 on amino acid transport in bovine brain microvessel endothelial cells.

Authors:  Xiaobin Zhang; Daria Y Alakhova; Elena V Batrakova; Shu Li; Zhihui Yang; Yili Li; Alexander V Kabanov
Journal:  J Neuroimmune Pharmacol       Date:  2008-08-02       Impact factor: 4.147

3.  Coadministration of branched-chain amino acids and lipopolysaccharide causes matrix metalloproteinase activation and blood-brain barrier breakdown.

Authors:  Giselli Scaini; Meline O S Morais; Leticia S Galant; Francieli Vuolo; Dhébora M Dall'Igna; Matheus A B Pasquali; Vitor M Ramos; Daniel P Gelain; Jose Claudio F Moreira; Patrícia F Schuck; Gustavo C Ferreira; Francisco G Soriano; Felipe Dal-Pizzol; Emilio L Streck
Journal:  Mol Neurobiol       Date:  2014-01-05       Impact factor: 5.590

4.  Investigation of inflammatory profile in MSUD patients: benefit of L-carnitine supplementation.

Authors:  Caroline Paula Mescka; Gilian Guerreiro; Bruna Donida; Desirèe Marchetti; Carlos Alberto Yasin Wayhs; Graziela Schimitt Ribas; Adriana Simon Coitinho; Moacir Wajner; Carlos Severo Dutra-Filho; Carmen Regla Vargas
Journal:  Metab Brain Dis       Date:  2015-05-24       Impact factor: 3.584

5.  Acute Administration of Branched-Chain Amino Acids Increases the Pro-BDNF/Total-BDNF Ratio in the Rat Brain.

Authors:  Giselli Scaini; Meline O S Morais; Camila B Furlanetto; Luiza W Kist; Talita C B Pereira; Patrícia F Schuck; Gustavo C Ferreira; Matheus A B Pasquali; Daniel P Gelain; José Cláudio F Moreira; Maurício R Bogo; Emilio L Streck
Journal:  Neurochem Res       Date:  2015-02-14       Impact factor: 3.996

6.  Serum Markers of Neurodegeneration in Maple Syrup Urine Disease.

Authors:  Giselli Scaini; Tássia Tonon; Carolina F Moura de Souza; Patricia F Schuk; Gustavo C Ferreira; Joao Seda Neto; Tatiana Amorin; Ida Vanessa D Schwartz; Emilio L Streck
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

Review 7.  Cytoskeleton as a potential target in the neuropathology of maple syrup urine disease: insight from animal studies.

Authors:  R Pessoa-Pureur; M Wajner
Journal:  J Inherit Metab Dis       Date:  2007-06-14       Impact factor: 4.982

8.  Behavioral responses in rats submitted to chronic administration of branched-chain amino acids.

Authors:  Giselli Scaini; Gabriela C Jeremias; Camila B Furlanetto; Diogo Dominguini; Clarissa M Comim; João Quevedo; Patrícia F Schuck; Gustavo C Ferreira; Emilio L Streck
Journal:  JIMD Rep       Date:  2013-11-09

9.  Oxidative stress in plasma from maple syrup urine disease patients during treatment.

Authors:  Alethéa G Barschak; Angela Sitta; Marion Deon; Amanda T Barden; Carlos S Dutra-Filho; Moacir Wajner; Carmen R Vargas
Journal:  Metab Brain Dis       Date:  2007-11-17       Impact factor: 3.584

10.  Dual mechanism of brain injury and novel treatment strategy in maple syrup urine disease.

Authors:  William J Zinnanti; Jelena Lazovic; Kathleen Griffin; Kristen J Skvorak; Harbhajan S Paul; Gregg E Homanics; Maria C Bewley; Keith C Cheng; Kathryn F Lanoue; John M Flanagan
Journal:  Brain       Date:  2009-03-17       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.